Study of Improving Insulin Sensitivity by Electroacupuncture Therapy

This study has been completed.
Sponsor:
Collaborator:
China Medical University, China
Information provided by:
China Medical University Hospital
ClinicalTrials.gov Identifier:
NCT00379379
First received: September 20, 2006
Last updated: NA
Last verified: September 2006
History: No changes posted
  Purpose

The aim of this study is to find out whether the hypoglycemic and improving insulin resistance effect will appear or not, when EA applying on specific acupoints of NIDDM patients.


Condition Intervention
Diabetes Mellitus, Type 2
Insulin Resistance
Device: electroacupuncture

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Study of Improving Insulin Sensitivity by Combined Both Electroacupuncture and Drug Therapy

Resource links provided by NLM:


Further study details as provided by China Medical University Hospital:

Primary Outcome Measures:
  • Hypoglycemic activity, plasma insulin level, HOMA index

Secondary Outcome Measures:
  • Triglyceride, cholesterol, free fatty acid

Estimated Enrollment: 26
Study Start Date: January 2005
Estimated Study Completion Date: December 2005
Detailed Description:

Some previous animal model studies reveal that electroacupuncture (EA) applying on specific acupoints, such as Zhongwan and Zusanli acupoint, can reduce plasma glucose levels and encourage insulin secretion, even improve insulin resistance. In this study, we want to observe these results on type II diabetic patients who have been diagnosed in five years under a study design of randomized control trial (RCT) to obtain evidence on clinical.

We undertook a randomized, single blind and sham group controlled study to evaluate the effect of EA with a frequency in 15 Hz and fixed intensity (10 mA) on human Zusanli acupoint. A total of 26 newly diagnostic type II diabetic patients are enrolled in this study. They are randomly divided into 2 groups. There are 13 patients in the experimental group (EG) with EA treatment, and the other 13 patients are divided into control group (CG) with sham treatment. The main outcome is the changes of laboratory parameters between before and 30 minutes after the test.

  Eligibility

Ages Eligible for Study:   30 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • newly diagnosed NIDDM patient within 5 years
  • age between 30 to 65 years old
  • controlled BP below 140/90 mmHg
  • oral hypoglycemic agent (OHA) therapy with Gliclazide twice per day.

Exclusion Criteria:

  • disorders of hemostasis
  • patient had received insulin therapy
  • severe disease such as CVA, CAD within 6 months
  • Arrhythmia history and on pacemaker.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00379379

Locations
Taiwan
Graduate Insititude of Integration Chinese And Western Medicine, China Medical University
Taichung, Taiwan, 40402
Sponsors and Collaborators
China Medical University Hospital
China Medical University, China
Investigators
Principal Investigator: Shih-Liang Chang, M.D., Ph.D. Graduate Institude of Integration Chinese and Western Medicine, China Medical University
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00379379     History of Changes
Other Study ID Numbers: DMR93-IRB-127
Study First Received: September 20, 2006
Last Updated: September 20, 2006
Health Authority: Taiwan: Department of Health

Keywords provided by China Medical University Hospital:
electroacupuncture, plasma glucose, plasma insulin

Additional relevant MeSH terms:
Insulin Resistance
Diabetes Mellitus, Type 2
Diabetes Mellitus
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 16, 2014